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Abstract
Introduction: Longer intervals between clinic consultations for clinically stable antiretroviral therapy (ART) patients may
improve retention in care and reduce facility workload. We assessed long-term retention among clinically stable ART patients
attending six-monthly clinical consultations (SMCC) with three-monthly fast-track drug refills, and estimated the number of
consultations “saved” by this model of ART delivery in rural Malawi.
Methods: Stable patients (aged ≥18 years, on first-line ART ≥12 months, CD4 count ≥300 cells/mL3, without opportunistic
infections, not pregnant/breastfeeding) were eligible for SMCC, with three-monthly drug refills from community health work-
ers. Early enrollees were those starting SMCC within six months of eligibility, while late enrollees started at least 6 months
after first eligibility. Kaplan–Meier methods were used to calculate cumulative probabilities of retention, stratified by timing of
their enrolment and from first six-monthly clinical consultation. Cox regression was used to measure attrition hazards from
the first six-monthly clinical consultation and risk factors for attrition, accounting for the time-varying nature of their eligibility
and enrolment in this model of care.
Results: From 2008 to 2015, 22,633 clinically stable patients from 11 facilities were eligible for SMCC for at least three
months, contributing 74,264 person-years of observation, and 18,363 persons (81%) initiated this model of care. The median
time from eligibility to enrolment was 12 months and the median cumulative time on SMCC was 14.5 months. Five years after
first SMCC eligibility, cumulative probabilities of retention were 85.5% (95% CI: 84.0% to 86.9%) among early enrollees and
93% (95% CI: 92.8% to 94.0%) among late enrollees. The cumulative probability of retention from first SMCC was 97.0% (95%
CI: 96.7% to 97.3%) and 86% (95% CI: 85% to 87%) at one and five years respectively. Among eligible patients initiating SMCC,
the adjusted hazards of attrition were 2.4 (95% CI: 2.0 to 2.8) times higher during periods of SMCC discontinuation compared
to periods on SMCC. Male sex, younger age, more recent SMCC eligibility and WHO Stage 3/4 conditions in the past year were
also independently associated with attrition from SMCC. Approximately 26,000 consultations were “saved” during 2014.
Conclusion: After five years, retention among patients attending SMCC was high, especially among women and older patients,
and its scale-up could facilitate universal access to ART.
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1 | INTRODUCTION
In 2015, the World Health Organization (WHO) recom-
mended immediate initiation of antiretroviral therapy (ART)
for people living with HIV after their diagnosis, regardless of
their immunological status [1], following evidence from ran-
domized controlled trials and observational studies of its indi-
vidual health benefits and prevention effects [2,3]. This
approach holds great potential for reducing HIV-related mor-
bidity and mortality in sub-Saharan Africa, if wide-scale adop-
tion of the WHO guidelines can be coupled with excellent
rates of adherence to treatment [4].
Achieving these goals requires improvements in HIV testing
and ART initiation rates, as well as in retention in care. In
Malawi, substantial progress has been made towards achieving
the The Joint United Nations Programme on HIV/AIDS
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(UNAIDS) 90-90-90 targets, with data from a household-based
national survey conducted in 2015 to 2016 indicating that 73%
of people living with HIV aged 15 to 64 years reported know-
ing their HIV status, of whom 89% self-reported current use of
ART, and of whom 91% were virally suppressed [5]. With self-
testing for HIV being scaled up in many countries including
Malawi, HIV patient numbers are likely to further increase in
the future, and may surpass health facility capacity, unless inno-
vative models of ART delivery are widely adopted.
Differentiated models of HIV care have been advocated as
a strategy for managing clinically stable patients by reducing
the number of consultations in HIV clinics, which would free
up health worker time to initiate new patients onto ART, and
better address the needs of patients needing additional moni-
toring [6-11]. Furthermore, given that frequently cited barri-
ers to appointment attendance include distance to health
facilities, waiting times, competing responsibilities such as
employment, and concerns over being seen [12-15], patient-
centred models of care that addressed these issues may
improve retention in care [7,16].
Differentiated models of ART delivery can be broadly classi-
fied into individual models (facility or out-of-facility) and group
models (health worker or client-managed) [6]. Several group
and out-of-facility individual models have demonstrated
promising results, including health worker-led ART refill
groups in South Africa [17], patient-led community ART
groups in Mozambique [18-21] and community ART distribu-
tions points in the Democratic Republic of Congo [22]. How-
ever, health worker-managed or patient-managed group
strategies may require additional resources in order to scale-
up implementation, and concerns have been raised about their
sustainability [23,24]. The facility-based individual model
should require fewer resources as it only involves appoint-
ment-spacing of facility-based clinical consultations and drug
refills for stable patients [6]. Appointment-spacing allows clini-
cally stable patients to attend HIV clinics less frequently for
clinical assessments than the one or two-monthly appoint-
ments required in many countries for ART patients, with drug
refills provided between clinical consultations by lower cadre
health workers [6,25].
To date, there is a dearth of evidence from African settings
on the effectiveness of facility-based individual models of dif-
ferentiated care, including data on long-term retention rates
and risk factors for attrition from care among patients
enrolled in these models [26]. The inclusion of differentiated
ART delivery in the WHO guidelines since 2016 has been
accompanied by calls to generate more evidence from demon-
stration projects of differentiated ART delivery on patient out-
comes to facilitate their adoption within national HIV
programmes, which will be key to achieving the UNAIDS 90-
90-90 targets [6-8,10,26,27]. Analyses of routinely collected
programme data, where facility-based individual models have
been introduced, can provide useful evidence on enrolment
rates and long-term treatment outcomes in programmatic set-
tings, as well as insights into potential reductions in patient
numbers within health facilities following its introduction. This
paper describes long-term retention in care, and risk factors
for attrition from care among clinically stable ART patients who
initiate six-monthly clinical consultations (SMCC) with fast-track
three-monthly refills from facility-based community health
workers in Chiradzulu District, Malawi over the period from
2008 to 2015, where Medecins sans Frontieres (MSF) has
been supporting the Ministry of Health’s (MoH) HIV pro-
gramme. We additionally estimate the number of clinic appoint-
ments “saved” as a result of its implementation since 2008.
2 | METHODS
2.1 | Study setting
MSF has supported the Malawian MoH provision of HIV and
tuberculosis services to around 270,000 persons in Chiradzulu
district in southern Malawi since 1997 [28]. Free ART is avail-
able from the district hospital and 10 health centres. By
2013, HIV prevalence was 17%, and 77% of persons living
with HIV had been diagnosed, 67% were on ART and 62%
were virally suppressed [29].
2.2 | The differentiated model of ART delivery
From January 2008, adult patients attending any HIV clinic in
the district’s health facilities were screened by a clinical officer,
and those meeting eligibility criteria (see Table 1) were offered
enrolment on the SMCC schedule consisting of health facility
appointments for clinical assessments every six months, instead
of every one or two months, and provision of a three-month
drug supply. Health surveillance assistants (HSA), who are paid
community health workers, recruited and trained by the MoH
and MSF, provided three-monthly ART refills from each health
centre or hospital pharmacy in between the SMCC, assessed
adherence and monitored patients’ health and pregnancy status
using a standardized assessment tool. Those on SMCC who were
assessed by HSAs as having become no longer eligible (i.e. were
pregnant, unwell or with adherence concerns) and patients
choosing to opt-out of SMCC (or wishing to seek medical care
before their next scheduled SMCC) returned to their previous
ART schedule at an HIV clinic of their choice and received clinical
care as required. The main characteristics of the differentiated
model of care, including eligibility criteria are summarized in
Table 1 and further details can be found elsewhere [30].
2.3 | Study design and data collection
We undertook a retrospective cohort analysis using data
extracted from an electronic database where visit-level data
on patient records were routinely entered for programme
monitoring purposes. Socio-demographic characteristics were
captured during the patient’s first visit to the clinic, and clini-
cal, immunological, pharmacy and adherence data were col-
lected at follow-up visits. Copies of follow-up forms were
forwarded from each health centre to a centralized location at
the end of each day for data entry into an electronic database
by trained clerks.
2.4 | Data analysis
The study population included patients who were ever eligible
for SMCC between January 2008 and July 2015. The baseline
CD4 count and WHO stage measures were defined as the
most recent results available up to one year prior to SMCC
eligibility and one year prior to SMCC start. Pregnancy status
was inferred from the number of weeks of amenorrhoea, and
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was used to define first and last possible pregnancy dates.
Health facilities were defined as medium if they served a
catchment population of approximately 15,000 to 25,000 per-
sons, and as large if they served a population of over 25,000.
Kaplan–Meier probabilities for retention were calculated (i)
after first eligibility date, stratified by enrolment status (never
enrolled, early enrollee (within six months of first eligibility) or
late enrollee (enrolled at least 6 months after first eligibility
date)) and (ii) after first SMCC appointment. Attrition was
defined as either reported death, or loss to follow-up, with
lost to follow-up recorded for patients more than 60 days late
for their last scheduled appointment. Cox proportional hazards
regression was used to estimate crude and adjusted hazard
ratios for attrition up to five years after first SMCC, and to
identify risk factors for attrition. Eligibility and enrolment onto
the SMCC schedule were considered as time-dependent vari-
ables since patients could become ineligible for periods of
time, for example if they became pregnant, but could later
return to being eligible. Similarly, SMCC-enrolled patients
could leave and re-enter the six-monthly schedule, either due
to changing eligibility status or for other reasons including a
desire to return to shorter durations between appointments.
In five health centres, routine viral load monitoring was
implemented from August 2013 in line with MoH protocols
(at six and twenty-four months after ART initiation and bian-
nually thereafter). Among patients attending these health cen-
tres, the proportions with an undetectable viral load (defined
as <1000 copies/mL) and the median time from SMCC initia-
tion to viral load test were reported.
In order to calculate the total number of clinical appoint-
ments that were “saved” per year since SMCC introduction,
we classified each patient visit as being either eligible or ineli-
gible for SMCC. Eligible visits were further classified as: (a) a
SMCC visit; (b) a drug refill visit with an HSA; or (c) routine
visit (i.e. a non-SMCC clinic visit among an SMCC-eligible
patient) and aggregated over a 12-month period. The esti-
mated number of appointments per category per year was
then presented graphically. We defined the annual number of
drug refill visits with an HSA as the annual number of clinical
consultations that were saved. The total number of clinical
appointments saved since the introduction of SMCC was cal-
culated by summing these annual totals over the years of
SMCC implementation.
2.5 | Ethics
Ethical approval was provided by the National Health Sciences
Research Committee in Malawi. As this is a secondary analysis
of routinely collected programme data which were anonymized
prior to analysis, consent for participation from patients was
not sought. This research fulfils the exemption criteria set by
the Medecins Sans Frontieres Ethics Review Board for a poste-
riori analysis of routinely collected clinical data.
3 | RESULTS
3.1 | Patient characteristics
In total, 47,904 patients aged 18 years and over were seen
between January 2008 and July 2015, of whom 26,081 ever
met the eligibility criteria for SMCC (Figure S1). The most
common reasons for not being eligible for SMCC were having
Table 1. Key characteristics of the differentiated model of ART delivery and the previous standard model of ART delivery
SMCC with fast-track refills for eligible patients
ART delivery model
prior to Jan 2008
and for non-SMCC patients
Jan 2008 to
July 2013
Aug 2013
to Dec 2013
Jan 2014
to Dec 2014
Jan 2015
to July 2015
Eligibility criteria
Age ≥18 years ≥18 years ≥18 years ≥18 years –
Time on first-line ART ≥12 months ≥12 months ≥12 months ≥12 months, or ≥6 months
if VL ≤ 1000 copies/mL
–
Most recent CD4 (cells/mL3)
or VL (copies/mL)
CD4 ≥ 300 CD4 ≥ 300
or VL ≤ 1000
CD4 ≥ 200
or VL ≤ 1000
CD4 ≥ 200 or VL ≤ 1000 –
All time periods:
ART intolerance No intolerance to ART –
Opportunistic infections No current tuberculosis or Kaposi’s sarcoma within last year –
Pregnancy status Not pregnant, no children <2 years old –
Who?
Clinical consultation Clinical officer Clinical officer
ART refill Health surveillance assistant (community health worker) Clinical officer
When?
Clinical consultation Every six months Every one to two months
ART refill Every three months Every one to two months
Monitor eligibility Every three months n/a
Where? Health facility of patient’s choice Health facility of patient’s choice
ART, antiretroviral therapy; SMCC, six-monthly clinical consultations; VL, viral load.
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not yet initiated ART (n = 9615), having spent less than
12 months on ART (n = 7069) and having a baseline CD4
lower than the required threshold (n = 2282). Of those who
were ever eligible for SMCC, 22,633 (87%) had at least three
months of eligibility, and were included in the analyses, con-
tributing 74,264 person-years of observation.
Of the 22,633 individuals in the analysis (66% female), 19%
never enrolled, 31% were early enrollees and 50% were late
enrollees (Table 2). 18,363 (81%) of eligible patients initiated
SMCC. At first SMCC, 66% of patients were women, and the
majority were 25 years of age or older. Just over half were
attending a medium-sized health facility and 92% had a
baseline CD4 count >300 cells/mm3, with a median duration
since the CD4 count measurement of eight months. The med-
ian number of months from first eligibility for SMCC to start-
ing the SMCC schedule was 12 months [interquartile range
(IQR): 3 to 27 months].
3.2 | Median cumulative time spent in states of
SMCC enrolment and eligibility
Following first eligibility for SMCC, patients who never initi-
ated the SMCC schedule spent a median cumulative time of
12 months being eligible for SMCC and 10 months being no
Table 2. Baseline characteristics of (i) participants ever eligible for SMCC by enrolment category and (ii) participants at first SMCC
Variable
At first SMCC eligibility date
At first SMCC visit
Never enrolled Late enrollee Early enrollee All enrollees
N = 4270 N = 11,240 N = 7123 N = 18,363
n (%) n (%) n (%) n (%)
Sex
Male 1398 (33) 3508 (31) 2678 (38) 6186 (34)
Female 2872 (67) 7732 (69) 4445 (62) 12,177 (66)
Age
18 to 24 306 (7) 368 (3) 259 (4) 420 (3)
25 to 34 1508 (35) 3388 (30) 2436 (34) 4945 (27)
35 to 44 1289 (30) 4262 (38) 2765 (39) 7206 (39)
≥45 1167 (27) 3222 (28) 1663 (23) 5792 (31)
Year of first SMCC eligibility
2008 to 2009 1002 (23) 4137 (37) 863 (12) n/a
2010 to 2011 792 (19) 3080 (27) 1088 (15) n/a
2012 to 2013 1096 (26) 3399 (30) 2341 (33) n/a
2014 to 2015 1380 (32) 624 (5) 2831 (40) n/a
Size of health centre
District hospital 940 (22) 2346 (21) 700 (10) 3046 (17)
Large health centre 1111 (26) 3238 (29) 2502 (35) 5740 (31)
Medium health centre 2179 (51) 5520 (49) 3921 (55) 9441 (51)
Other 40 (1) 136 (1) 0 (0) 136 (1)
Months since last CD4 result
Median [IQR] 3 [1 to 8] 3 [1 to 6] 3 [1 to 6] 12 [3 to 26]
CD4 count in past year
<300 516 (12) 357 (3) 727 (10) 1231 (7)
300 to 499 1822 (43) 5837 (52) 2945 (41) 6548 (36)
≥500 1334 (31) 4195 (37) 2701 (38) 8999 (49)
Missing 598 (14) 851 (8) 750 (11) 1585 (9)
WHO Stage 3/4 in past year
Yes 2363 (55) 6105 (54) 2617 (37) 9189 (50)
No 1907 (45) 5135 (46) 4506 (63) 9174 (50)
Months since first clinic visit
Median [IQR] 28 [15 to 50] 29 [16 to 49] 28 [16 to 48] 48 [29 to 72]
Months since ART start
Median [IQR] 19 [12 to 35] 18 [12 to 35] 15 [12 to 28] 35 [23 to 60]
Months since first SMCC eligibility
Median [IQR] n/a n/a n/a 12 [3 to 27]
SMCC, six-monthly clinical consultations; ART, antiretroviral therapy; IQR, interquartile range.Statistical significant differences were observed for
all variables comparing never enrolled, late enrollee and early enrollee (Pearson chi-square, p < 0.05).
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longer eligible for SMCC (Figure 1). Among late enrollees,
these durations prior to starting SMCC were broadly similar.
The cumulative median total time spent eligible and on SMCC
for late enrollees was only 12 months, while a further median
of six months was spent being no longer on SMCC regardless
of eligibility. Among early enrollees, as expected, time spent
being eligible but not yet started on SMCC, or no longer eligi-
ble and not yet started on SMCC, was much shorter at approx-
imately three months each. As with late enrollees, the
cumulative median total time spent eligible and on SMCC
among early enrollees was only just over one year, while a fur-
ther median of six months was spent being no longer on SMCC
regardless of eligibility. Interruptions to SMCC eligibility were
less frequent among patients who enrolled early onto SMCC
(16.0% compared to 36.2% among those never enrolled and
38.0% among late enrollee (p < 0.001, data not shown)).
3.3 | Probability of retention by SMCC enrolment
category and from first SMCC
The median time retained in care after first SMCC eligibility
was 3.2 years [IQR: 1.6 to 5.0]. The cumulative probability of
retention in care one year after first SMCC eligibility was
86.8% (95% CI: 85.6% to 87.8%) among those who never
enrolled, 97.3% (95% CI: 96.8% to 97.6%) among early SMCC
enrollees and 99.8% (95% CI: 99.7% to 99.9%) among late
SMCC enrollees, while the corresponding figures at five years
were 47.4% (95% CI: 45.0% to 49.7%), 85.5% (95% CI: 84.0%
to 86.9%) and 93.4% (95% CI: 92.8% to 94.0%) respectively
(Figure 2a). Among all patients who ever initiated SMCC, the
median time retained in care was 1.2 years [IQR: 0.7 to 3.0].
The cumulative probability of retention at one year was
97.0% (95% CI: 96.7% to 97.3%) and at five years was 86%
(95% CI: 85% to 87%) (Figure 2b).
3.4 | Crude and adjusted hazard ratios for attrition
Among those who ever started on the SMCC schedule, most
of the follow-up time was spent being both eligible and
enrolled on SMCC, during which the rate of attrition was
26.4/1000 person-years (Table 3). The crude hazards ratio for
attrition was 2.3 (95% CI: 2.0 to 2. 8) in the period when
patients were eligible but off SMCC and 2.3 (95% CI: 1.8 to
2.9) in the periods when patients were no longer eligible and
off SMCC, when compared with periods when patients were
both eligible for SMCC and following the SMCC schedule. In
the unadjusted Cox models, the hazard of attrition was also
higher in men, those aged 18 to 24 years and 25 to 34 years,
those more recently eligible for SMCC, those with no
recorded CD4 counts in the year prior to initiating SMCC,
those with shorter durations on ART and those with WHO
Stage 3/4 conditions in the past year.
In the adjusted models, patients had 2.6 times higher haz-
ards of attrition (95% CI: 2.2 to 3.1) during periods when
patients were eligible but no longer on SMCC, and 2.4 (95%
CI: 1.9 to 3.0) times higher hazards of attrition during periods
when patients were not eligible and off SMCC, compared to
periods when they were both eligible and enrolled on SMCC
There was no difference in adjusted hazards of attrition
among patients during periods when they were not eligible
and on SMCC compared to periods when they were eligible
and on SMCC (adjusted hazard ratio (aHR) = 1.2; 95% CI: 0.8
to 1.8). In the adjusted models, there was an increased hazard
of attrition among patients aged 18 to 24 years (aHR 2.6,
95% CI: 1.9 to 3.4) and in those aged 25 to 34 years (aHR
1.3, 95% CI: 1.1 to 1.5) compared to patients aged 35 to
44 years, and among men compared to women (aHR 1.3, 95%
CI: 1.2 to 1.5). There was a trend in increased attrition haz-
ards with more recent calendar years of SMCC eligibility
(p < 0.01). Patients with recorded WHO Stage 3/4 conditions
in the past year had higher attrition hazards compared to
those who did not (aHR 1.2, 95% CI: 1.0 to 1. 3).
3.5 | Virological outcomes
In total, 4649 patients who were ever eligible for SMCC first
enrolled on the SMCC schedule at one of five health centres
between August 2013 and July 2015 where routine viral load
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Figure 1. Cumulative median time spent in different states of SMCC eligibility and enrolment, stratified by enrolment category.
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testing was available. Of these patients, at least one viral load
measurement was available for 1742 (38%) individuals. Of
these, 93% (n = 1619) of viral load measurements were
<1000 copies/mL. The viral load test was done a median of
21 months following first SMCC enrolment [IQR: 14 to 28].
3.6 | Appointment savings
In 2008, when the strategy was first introduced, a total of
110,389 clinic visits were recorded across the 11 facilities
among patients ≥18 years of age (Figure 3). As the strategy
was rolled out, the number of routine visits among patients
who never became eligible for differentiated ART (including
those not yet on ART) increased steadily from under 37,000
per year to approximately 52,000 by 2014. The number of vis-
its made by patients who were eligible for SMCC at that par-
ticular visit, but who had not yet enrolled on SMCC, peaked at
just under 41,000 in 2013, and represents appointments that
could have been saved if the programme had been able to initi-
ate all eligible patients onto the SMCC schedule. The number
of SMCC visits per year increased from <500 in 2008 to just
over 26,000 during 2014, and corresponds to the increase in
the number of three-monthly drug refill visits made by SMCC
patients to the HSAs that is the number of clinic visits “saved”
as a result of SMCC implementation. Over the period from
2008 to 2014, the total number of visits “saved” equates to
just short of 62,000. The annual total number of visits in the
health facilities only starts to decline in 2013 from a peak of
161,619 due to the gradual rollout of SMCC.
4 | DISCUSSION
Our results indicate that SMCC with three-monthly ART refills
from community health workers represents a feasible and
effective strategy for delivering first-line ART in this rural Afri-
can district. The cumulative probability of retention was high
among both early and late SMCC enrollees following their eligi-
bility for SMCC, and also high among all patients following
SMCC initiation with 97% and 86% retained after one and five
years respectively of follow-up. These retention rates compare
very favourably with those previously observed among adults
on first-line ART in this setting, as well as elsewhere [31,32],
and are also broadly in line with those reported from studies
reporting on other differentiated models of care [17,19,33].
Although the hazards of attrition were low among eligible
patients who initiated SMCC, the adjusted hazards of attrition
were 2.6 (95% CI: 2.2 to 3.1) times higher during periods of
SMCC discontinuation compared to periods on SMCC, sug-
gesting the need for careful patient monitoring among
patients who discontinue SMCC. As with traditional models of
ART delivery in many settings [34], men and young adults
aged 18 to 24 years of age had higher attrition risks, indicat-
ing that differentiated models of care may not be sufficient to
overcome age- and sex-specific barriers to optimal ART out-
comes, and that men and young people may require additional
support or alternative differentiated care models to remain
engaged with HIV care and treatment. Attrition risks were
also lower for earlier patient cohorts, reflecting the longer
average time spent being eligible for SMCC before enrolment,
and the accompanying selection effects that meant that they
were well-established patients with excellent adherence histo-
ries by the time that they initiated SMCC.
Although 81% of all eligible patients were initiated on to
SMCC, there was a median time of 12 months from first eligi-
bility to first SMCC. Furthermore, the cumulative median time
on SMCC was relatively short at 14 months among early and
late enrollees, suggesting that efforts are needed to reduce the
delay between becoming eligible for SMCC and moving to this
schedule. Although further research is needed to understand
and address patient and health systems barriers to SMCC
uptake, it is likely that further health worker training on applica-
tion of the SMCC protocols and ensuring patient readiness
may reduce delays in SMCC initiation following eligibility.
This model of differentiated ART delivery in this setting
saved just under 62,000 clinical consultations over seven
years, despite the slow pace of the rollout. Assuming that a
typical clinical officer conducts around 500 consultations per
month, the total savings equates to almost 118 clinician-
months or approximately 10 clinician-years for the health facil-
ities in this district over the study period. During 2014,
approximately 26,000 appointments had been moved outside
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Figure 2. (a) Cumulative probability of retention in HIV care among
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the clinic during the year as a result of SMCC, corresponding
to approximately sixty clinician-months or five clinician-years,
and representing a substantial saving in health worker time in
a country with severe workforce shortages.
These findings demonstrate that SMCC can play a key role
in enabling ART programmes to continue their expansion as
test and treat policies are introduced, by freeing up health
worker time to initiate new patients on ART, and manage
complicated cases such as patients with suspected treatment
failure, opportunistic infections, or those taking second-line
regimens. Furthermore, this model of care is likely to be scal-
able in Malawi, and elsewhere, because the strategy requires
fewer formally trained health workers and no additional
resources than the current standard of care.
The findings from our analysis are consistent with studies
investigating the effectiveness of community-based or group-
Table 3. Rates, unadjusted, and adjusted hazard ratios from Cox regression for attrition among participants who ever started SMCC
All patients (N = 18,363) Attritions Person-years (py) Attrition rate/1000 py
Unadjusted Cox model Adjusted Cox modela
cHR (95% CI) p-value aHR (95% CI) p-value
SMCC periods
Eligible and off SMCC 188 3584 52.5 2.3 (2.0 to 2.8) <0.01 2.6 (2.2 to 3.1) <0.01
Eligible and on SMCC 751 28,466 26.4 1.0 1.0
Not eligible and off SMCC 87 1713 50.8 2.3 (1.8 to 2.9) <0.01 2.4 (1.9 to 3.0) <0.01
Not eligible and on SMCC 25 903 27.7 1.1 (0.7 to 1.6) 0.7 1.2 (0.8 to 1.8) 0.36
Sex
Male 404 11,750 37.9 1.2 (1.1 to 1.4) <0.01 1.3 (1.2 to 1.5) <0.01
Female 647 22,916 30.5 1.0 1.0
Age at baseline
18 to 24 54 778 53.1 2.6 (2.0 to 3.5) <0.01 2.6 (1.9 to 3.4) <0.01
25 to 34 347 10,102 34.4 1.3 (1.1 to 1.5) <0.01 1.3 (1.1 to 1.5) <0.01
35 to 44 368 13,899 26.5 1.0 1.0
≥45 282 25,380 28.5 1.1 (0.9 to 1.3) 0.41 1.1 (0.9 to 1.2) 0.44
Size of health centre
District hospital 152 4500 33.8 1.0 (0.9 to 1.2) 0.91 1.0 (0.9 to 1.3) 0.5
Large health centre 292 11,547 25.3 0.8 (0.7 to 0.9) <0.01 0.8 (0.7 to 0.9) <0.01
Medium health centre 601 18213 33.0 1.0 1.0
Other 6 405 14.8 0.5 (0.2 to 1.0) 0.05 0.6 (0.2 to 1.2) 0.15
Year of first SMCC eligibility
2008 to 2009 353 15,796 22.3 1.0 1.0
2010 to 2011 310 9535 32.5 1.5 (1.3 to 1.8) <0.01 1.7 (1.4 to 2.0) <0.01
2012 to 2013 300 7298 41.1 2.1 (1.7 to 2.4) <0.01 2.4 (2.0 to 2.9) <0.01
2014 to 2015 89 2037 43.7 2.2 (1.7 to 2.8) <0.01 2.3 (1.8 to 3.1) <0.01
Last pre-SMCC CD4
b
<300 36 984 50.7 1.2 (0.8 to 1.6) 0.41 0.9 (0.7 to 1.4) 0.78
300 to 499 420 13,807 33.5 1.0
≥500 523 18,544 30.7 0.9 (0.8 to 1.1) 0.24 1.0 (0.9 to 1.2) 0.89
Missing 72 133 68.2 1.7 (1.3 to 2.2) <0.01 1.7 (1.3 to 2.2) <0.01
Month since ART start
<24 months 386 12,337 31.3 1.2 (1.0 to 1.4) 0.05 0.9 (0.7 to 1.2) 0.33
24 to 47 months 457 15,799 28.9 1.1 (1.0 to 1.3) 0.20 1.1 (0.9 to 1.4) 0.5
≥48 months 316 11974 26.4 1.0 1.0
Month since first visit
<24 months 261 7685 34.0 1.2 (1.1 to 1.4) 0.04 1.1 (0.8 to 1.4) 0.49
24 to 47 months 429 16,011 26.8 1.0 (0.8 to 1.1) 0.64 0.8 (0.7 to 1.0) 0.05
≥48 months 469 16,413 28.6 1.0 1.0
Cumulative WHO Stage 3/4b
Recorded 572 18,140 31.6 1.1 (1.0 to 1.2) 0.17 1.2 (1.0 to 1.3) 0.02
Not recorded 479 16,526 29.0 1.0 1.0
SMCC, six-monthly clinical consultations; ART, antiretroviral therapy, cHR, crude hazard ratio; aHR, adjusted hazard ratio.
aAdjusted for all variables in the table; bpast year.
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based ART delivery strategies for clinically stable patients in
other settings [9,35] and emerging findings from studies on
individual, facility-based individual models [33,36]. Facility-
based individual models based on appointment-spacing may
be easier to implement, and thus possibly more likely to be
scaled up by national HIV programmes. Many African coun-
tries explicitly recommend differentiated models of HIV care
including appointment-spacing [27,37], in line with recent
guidelines from WHO and the International AIDS Society that
recommend differentiated models of HIV care for clinically
stable ART patients [6,10,11].
There are various limitations that need to be considered
when interpreting these findings, including those inherent to
using routinely collected programmatic data such as missing
information that could influence classifications of SMCC eligi-
bility, or result in residual confounding (e.g. factors relating to
marital status or partner use of HIV services). In particular,
better documentation of reasons for delayed initiation and
non-initiation of SMCC among apparently eligible patients would
help to understand the poorer outcomes among this group
which precluded us from using them as a comparison group in
our analyses, due to selection biases that this would introduce
[26]. Documentation of reasons for leaving the SMCC schedule,
despite remaining eligible, would help assess reverse causality,
and aid interpretation of the relatively high attrition hazards
during these post-SMCC periods. Furthermore, we were not
able to measure mortality as an outcome, as the true status of
patients who are lost to follow-up from the clinic are not ascer-
tained, and will thus include deaths, defaulters and undocu-
mented transfers to other clinics. Nevertheless, as patients in
the programme are given a copy of their records, and are per-
mitted to attend other HIV clinics in the district for ART consul-
tations, we expect that the number of undocumented transfers
between clinics should be low, and thus attrition is likely to clo-
sely align to mortality. A further limitation was our inability to
investigate virological outcomes among all SMCC patients since
routine viral load testing was only introduced progressively in
the district from 2013. Although the preliminary findings among
the patients with viral load results are promising, future analyses
should include viral load as a primary outcome measure to bet-
ter ascertain the implications of SMCC on adherence, and this
will become increasingly possible as viral load monitoring
becomes more widespread.
Previous studies reporting retention rates among patients
receiving ART through other models of differentiated care
have had shorter follow-up periods [18,33,35]. The strength of
this study was the ability to document retention over a five-
year follow-up period as well as the possibility of including all
HIV clinics within one district, resulting in a large cohort of
patients under observation.
While these findings provide a much-needed and widely
called for contribution to the evidence base on differentiated
models of ART delivery [7,10,27], our results also highlight
several priorities for further research. This includes identifying
the optimal time at which appointment-spacing should start
for first-line ART patients and documentation of discontinua-
tion rates, reasons and associated risk factors. Furthermore,
qualitative studies are needed to elicit provider and patient
perspectives on this model of care, including underlying rea-
sons for its success, and to better understand why some
SMCC-eligible patients opt for the standard model of ART
delivery. Such research could facilitate greater engagement of
patients in further refining the SMCC model to best suit their
needs, address their concerns and enhance its performance.
5 | CONCLUSION
In conclusion, our findings demonstrate that SMCC with fast-
track refills for clinically stable, first-line ART patients represents
an effective and feasible strategy for delivering treatment,
enabling substantial savings in terms of health worker input, pro-
viding more flexible access to care and achieving excellent out-
comes under routine programme conditions. Further scale-up of
facility-based consultation-spacing strategies with three-monthly
fast-track ART refills from community health workers should be
encouraged, accompanied by ongoing programme monitoring
and evaluation in other settings, as an important step towards
achieving universal access to ART and a future free of AIDS.
AUTHORS ’ AFF I L IAT IONS
1Department of Population Health, London School of Hygiene and Tropical
Medicine, London, UK; 2Independent consultant, Berlin, Germany; 3Medecins
sans Frontieres, Paris, France; 4Medecins sans Frontieres, Chiradzulu, Malawi;
5Epicentre, Paris, France
COMPET ING INTERESTS
None to declare.
AUTHORS ’ CONTR IBUT IONS
AW, SN and CC designed the study; CM, CC and SN oversaw the data manage-
ment; SN, CC and AW designed or undertook the analysis; AW, SN, CC, ES, LS
and EP interpreted the data; AW and CC wrote the first draft of the manu-
script. All authors provided comments which were incorporated into subsequent
drafts by AW.
ACKNOWLEDGEMENTS
We thank the health workers and field teams involved in providing HIV care
and collecting these routine data in Chiradzulu. We also thank Sharon Perry for
her contributions during an early stage of the project and to Jim Todd for help-
ful comments on an earlier version of this manuscript.
FUNDING
The funding source had no role in the writing of the manuscript or the decision
to submit it for publication. AW, the corresponding author, had full access to
–40,000
0
40,000
80,000
120,000
160,000
1 2 3 4 5 6 7
N
um
be
r 
of
 c
on
su
lta
tio
ns
Year
Never SMCC eligible Routine visits pre-eligibility Routine visits post-eligibility SMCC Drug Refill
Figure 3. Estimated annual number of clinic appointments by
appointment type.
Wringe A et al. Journal of the International AIDS Society 2018, 21:e25207
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25207/full | https://doi.org/10.1002/jia2.25207
8
the data in the study and had final responsibility for the decision to submit for
publication. AW was supported by a Population Health Scientist award, jointly
funded by the UK Medical Research Council (MRC) and the UK Department
for International Development (DFID) under the MRC/DFID Concordat agree-
ment and is also part of the EDCTP2 programme supported by the European
Union.
REFERENCES
1. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure
prophylaxis for HIV. Geneva: WHO; 2015.
2. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initi-
ation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J
Med. 2015;373(9):795–807.
3. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of
early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med.
2015;373(9):808–22.
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal volun-
tary HIV testing with immediate antiretroviral therapy as a strategy for elimi-
nation of HIV transmission: a mathematical model. Lancet. 2009;373
(9657):48–57.
5. Malawi population-based HIV impact assessment 2015-2016. 2016 [cited
2018 June 11]. Columbia University. Available from: http://phia.icap.columbia.ed
u/wp-content/uploads/2016/09/MALAWI-Factsheet.FIN_pdf
6. IAS. Differentiated Care for HIV: It’s time to deliver differently. A decision
framework for antiretroviral therapy delivery. Geneva: International AIDS Soci-
ety; 2016.
7. Grimsrud A, Bygrave H, Doherty M, Ehrenkranz P, Ellman T, Ferris R, et al.
Reimagining HIV service delivery: the role of differentiated care from preven-
tion to suppression. J Int AIDS Soc. 2016;19(1):21484.
8. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies
in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman
T, et al. Sustainable HIV treatment in Africa through viral-load-informed differ-
entiated care. Nature 2015;528(7580):S68–76.
9. UNAIDS. Community-based antiretroviral therapy delivery: experiences from
MSF. Geneva: UNAIDS; 2015.
10. WHO. Consolidated guidelines on the use of antiretroviral drugs for treat-
ing and preventing HIV infection: recommendations for a public health approach.
2nd ed. Geneva: WHO; 2016.
11. A toolkit for health facilities: differentiated care for HIV and tuberculosis.
Geneva: The Global Fund; 2015.
12. Lankowski AJ, Siedner MJ, Bangsberg DR, Tsai AC. Impact of geographic
and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a
systematic review. AIDS Behav. 2014;18(7):1199–223.
13. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al.
Impact of HIV-related stigma on treatment adherence: systematic review and
meta-synthesis. J Int AIDS Soc. 2013;16 3 Suppl 2:18640.
14. Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A.
Patient-reported barriers and drivers of adherence to antiretrovirals in sub-
Saharan Africa: a meta-ethnography. Trop Med Int Health. 2010;15 Suppl 1:16–33.
15. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adher-
ence to HAART: a systematic review of developed and developing nation
patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.
16. Rasschaert F, Telfer B, Lessitala F, Decroo T, Remartinez D, Biot M, et al. A
qualitative assessment of a community antiretroviral therapy group model in
Tete, Mozambique. PLoS ONE. 2014;9(3):e91544.
17. Tsondai PR, Wilkinson LS, Grimsrud A, Mdlalo PT, Ullauri A, Boulle A. High
rates of retention and viral suppression in the scale-up of antiretroviral therapy
adherence clubs in Cape Town, South Africa. J Int AIDS Soc. 2017;20 Suppl
4:21649.
18. Bemelmans M, Baert S, Goemaere E, Wilkinson L, Vandendyck M, van Cut-
sem G, et al. Community-supported models of care for people on HIV treatment
in sub-Saharan Africa. Trop Med Int Health. 2014;19(8):968–77.
19. Decroo T, Telfer B, Dores CD, White RA, Dos Santos N, Mkwamba A,
et al. Effect of community ART Groups on retention-in-care among patients on
ART in Tete Province, Mozambique: a cohort study. BMJ Open. 2017;7(8):
e016800.
20. Auld AF, Shiraishi RW, Couto A, Mbofana F, Colborn K, Alfredo C, et al. A
decade of antiretroviral therapy scale-up in Mozambique: evaluation of
outcome trends and new models of service delivery among more than
300,000 patients enrolled during 2004-2013. J Acquir Immune Defic Syndr.
2016;73(2):e11–22.
21. Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Scho-
maker M, Mantangana N, et al. Effectiveness of patient adherence groups as a
model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape
Town, South Africa. PLoS ONE. 2013;8(2):e56088.
22. Vogt F, Kalenga L, Lukela J, Salumu F, Diallo I, Nico E, et al. Brief report:
decentralizing ART supply for stable HIV patients to community-based distribu-
tion centers: program outcomes from an urban context in Kinshasa, DRC.
J Acquir Immune Defic Syndr. 2017;74(3):326–31.
23. Rasschaert F, Decroo T, Remartinez D, Telfer BLessitala F, Biot M, et al.
Sustainability of a community-based anti-retroviral care delivery model - a quali-
tative research study in Tete, Mozambique. J Int AIDS Soc. 2014;17:18910.
24. Wilkinson L, Harley B, Sharp J, Solomon S, Jacobs S, Cragg C, et al. Expan-
sion of the Adherence Club model for stable antiretroviral therapy patients in
the Cape Metro, South Africa 2011-2015. Trop Med Int Health. 2016;21
(6):743–9.
25. Nakiwogga-Muwanga A, Katabira E, Sempa J, Kambugu A, Nakibuuka-Lub-
wama E, Lamorde M, et al. A pharmacy-only refill program at a large HIV clinic
in Uganda: experience and satisfaction of patients. J Int Assoc Provid AIDS
Care. 2014;13(3):264–8.
26. Mutasa-Apollo T, Ford N, Wiens M, Socias ME, Negussie E, Wu P, et al.
Effect of frequency of clinic visits and medication pick-up on antiretroviral treat-
ment outcomes: a systematic literature review and meta-analysis. J Int AIDS
Soc. 2017;20 Suppl 4:21647.
27. Grimsrud A, Barnabas RV, Ehrenkranz P, Ford N. Evidence for scale up: the
differentiated care research agenda. J Int AIDS Soc 2017;20 suppl 4:1–5.
28. National Statistical Office, I.M. Malawi demographic and health survey 2010.
Zomba, Malawi and Calverton (MD); 2011.
29. Maman D, Chilima B, Masiku C, Ayouba A, Masson S, Szumilin E, et al. Clo-
ser to 90-90-90. The cascade of care after 10 years of ART scale-up in rural
Malawi: a population study. J Int AIDS Soc 2016;19(1):20673.
30. IAS. 2018 [cited 2018 June 11]. Available from: http://www.differentiatedca
re.org/Models/MalawiFacilityFastTrack
31. McGuire M, Pinoges L, Kanapathipillai R, Munyenyembe T, Huckabee M,
Makombe S, et al. Treatment initiation, program attrition and patient treatment
outcomes associated with scale-up and decentralization of HIV care in rural
Malawi. PLoS ONE. 2012;7(10):e38044.
32. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in
low- and middle-income countries: systematic review and meta-analysis 2008-
2013. J Acquir Immune Defic Syndr. 2015;69(1):98–108.
33. Bekolo CE, Diallo A, Philips M, Yuma JD, Di Stefano L, Dreze S, et al. Six-
monthly appointment spacing for clinical visits as a model for retention in HIV
Care in Conakry-Guinea: a cohort study. BMC Infect Dis. 2017;17(1):766.
34. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M,
et al. Retention and risk factors for attrition among adults in antiretroviral treat-
ment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health.
2014;19(12):1397–410.
35. Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation
and operational research: community-based adherence clubs for the manage-
ment of stable antiretroviral therapy patients in Cape Town, South Africa: a
cohort study. J Acquir Immune Defic Syndr. 2016;71(1):e16–23.
36. Mody A, Roy M, Sikombe K, Savory T, Holmes C, Bolton-Moore C, et al.
Improved retention with six month clinic return intervals for stable HIV-infected
patients in Zambia. Clin Infect Dis 2018;66:237–43.
37. Consolidated guidelines for prevention and treatment of HIV in Uganda.
Uganda Ministry of Health Kampala. 2016.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Flow chart showing inclusion and exclusion for the
analysis.
Wringe A et al. Journal of the International AIDS Society 2018, 21:e25207
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25207/full | https://doi.org/10.1002/jia2.25207
9
